Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: Analysis of Expert and Community Healthcare Provider Practice Trends

With new indications for immune checkpoint inhibitors (ICIs), treatment decisions for patients with locally advanced (LA) and metastatic urothelial carcinoma (mUC) are becoming increasingly complex. The aim of this analysis was to assess real-world practice patterns for LA or mUC and compare them with recommendations from US experts based on patient cases entered by healthcare providers (HCPs) into an online decision support tool designed to provide specific, individualized expert recommendations.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings